

A PROJECT ON
“ALOPECIA AREATA”
IN
BACHELOR OF PHARMACY

Submitted By
Rahul Kumar Kushwaha
B. PHARMA 4TH YEAR
ENROLLMENT NO. 1712102066

Under the Supervision of
Dr Niranjan Kaushik
Associate Professor



GALGOTIAS
UNIVERSITY

SCHOOL OF MEDICAL AND ALLIED SCIENCE
GALGOTIAS UNIVERSITY
Greater Noida
APRIL,2021



DEPARTMENT OF PHARMACY
GALGOTIAS UNIVERSITY, GREATER NOIDA, G.B. NAGAR (U.P)

CERTIFICATE

This is to certify that the Project work entitled “**Alopecia Areata**” is a bonafide research work done by **Rahul Kumar Kushwaha** at Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, under the supervision and guidance of Dr Niranjan Kaushik, Associate Professor, School of Medical and Allied Sciences, Greater Noida. The work is completed and ready for evaluation in partial fulfilment for the award of Bachelor of Pharmacy under Galgotias University, Greater Noida during the academic year 2020-2021.

Date:

Place:

Prof. Pramod Kumar Sharma
Dean
School of Medical and Allied Sciences
Galgotias University

Dr. Niranjan Kaushik
Associate Professor
School of Medical and Allied Sciences
Galgotias University

CERTIFICATE

This is to certify that the project work entitled “**Alopecia Areata**” by Rahul kumar kushwaha for the award of “Bachelor of Pharmacy” degree, comprises of the bonafide research work done by him at Department of Pharmacy, School of Medical & Allied Sciences, Galgotias University, Greater Noida under my guidance and supervision and to my full satisfaction.

Dr. Niranjan Kaushik
Assistant Professor
School of Medical and Allied Sciences
Galgotias University
Greater Noida (U.P.)
(Guide)

DECLARATION

The project report entitled “**Alopecia Areata**” is the compilation work of **Mr. Rahul kumar kushwaha** under supervision of **Dr. Niranjana Kaushik** Associate Professor **Department of Pharmacy, GALGOTIAS UNIVERSITY Greater Noida U.P India.**

All pictures, Figures and information used in project are taken from various sources are true and best of my knowledge.

\

Date:

Place:

Rahul kumar kushwaha

ENROLLMENT No.1712102066



ACKNOWLEDGEMENT

Praise to be almighty God who made me able to carry out the present study successful. I feel high privileged while starting my dissertation work with acknowledge of the genuine help and support received from others who made this research and project possible for me. I deem it a great pleasure record my heartfelt gratitude to my supervisor, for her valuable guidance.

I express my gratitude to my friends and my co-workers for their moral support, advice, affection, co-operation, and functional freedom that made me to set goal and achieved this task. The episode of my acknowledgement would not be complete without mentioning thanks to **Dr. P.K. Sharma**, Dean of our School and Dr. Vijay Singh, HOD, Department of Pharmacy for sculpting another milestone in my academic journey.

Last but not the least I wish to express my gratitude to my lovely parents for their patience and constant support. They provided me with every opportunity to succeed.

Rahul Kumar Kushwaha

Abstract

Alopecia Areata is a common sort of not fearing going uncovered of head or conceivably body. Hereditary inclination, immunity, & ecological elements assume A significant part in pathogenesis of alopecia. Inconsistent alopecia is the most well-known structure. It is the most basic related situation. invade looking like “bee hive” is trademark on histo-pathology. Therapy is essentially engaged to show the symptomatic movement. Steroid are the favored medicines in type of skin, intraregional, or fundamental treatment. The most well-known site influenced is the scalp as singular or different site of alopecia. Histo-pathology is designed by a expanded number of hairs and present of provocative lymphocytics invade in the peribulbar area. Steroids is the very mainstreamd medicine for the therapy of this sickness. In this survey precisely the etiologies and pathogenics instruments, trials highlights, analysis & of the board of Alopecia-areata.

TABLE OF CONTENTS

- Introduction
- Dynamics of hair loss
- Etiopathogenesis
- Clinical features
- Quantitative hair loss
- Differential diagnosis
- Histopathology
- Management
- Conclusions
- References

- **Introduction**

Alopecia-Areata is typical reason for not panic hairfall that happens an inconsistent, blended example. This might include fall of hairs from a few spaces of the skin hair ,usually off crown [1]. Alopecia has revealed rate of 0.1-0.2 with a full life hazard of 1.6 percent with people get influenced similarly [2]. in long term imminent investigation noticed a frequency of 0.7 Percent in recent dermatologys patients [3]. The Etiology of Alopecia Areata has escapes specialists for quite long time and hence a large number of affiliations been given by analyst in the area of trichologys Perhaps most grounded affiliation is with immunity [4]. This review been upheld by the event of Alopecia in l relationship among other immune system problems like vitiligolichen planus, atopic, Hashimoto 'sthyroiditis ,perinicious frailty and sugar patients [5]. All the extra as of late, its been accounted for that there is maximum predominance state of mind, change, burdensome and uneasiness problems in sufferer of alopecia [6] it component mental dreariness broadly suspected two, a circumstances and logical results of AA. A multiprongeda proproceeding thusly justified In administration of such sufferers. Despite the fact that steroid is a pillar in diagnosis, a large exhibit Of proof based treatments have exits into front for the board of alopecia. The current examination endeavors to deliberately audit different viewpoints in the characteristic past of alopecia Areata & the advantages and disadvantages in diverse diagnosis modalitiess. Alopecia Areata is a typical reason for non fearing alopecia that happens In sketchy, intersecting or example. It might include fall of hair from a few spaces of the body In 1–2% of case the disease can grow whole head or the all inner layer of the skin Alopecia Has a revealed rate of minor with a lifetime hazard 1.7 percent with people been influenced.

- **DYNAMICS OF HAIR LOSS**

Hairs development happens cycless consist a large developing stage a small temporary stage and a small resting stage. Toward finish of The stable stage,hairs drops & another hair begins growing in the root starting the Cycles once more. There's a lot of significant varieties in the size of hair in three stage, in the term of the deciding the sort of hair grown especially size of hair . Typically around 100 number of hair arrive at the finish of their stable stage everyday & aftermath [7]. Balding basically addresses an issue of hairs [8]. It's accepted that in Alopecia Areata an at this point non identified problems invigorates a immune system lymphocytics assault. It irritationin explicit for anagens hairs Furthermore, capture. A disturbance of the developing stage, That is anagen capture, strange medically With tightened prximals closures & absence of roots. A relatedb But particular element noticed as often as possible in ladies. This term comprehensive of situation Where is the influenced hair go through a unexpected transformation from Anagens to telogens medically shaw as a restricted shields of hair in the and any

structurally differentiated A hair designed structure [9]. A relationship among hair it has been illustrated in detailed sufferers with Alopecia [10]. As of late, In USA exhibited that a Non HLA particle Includes the significant histo-compatibility A MICA is related with alopecia. It very well may be a potential up-and-comer quality and all-inclusive hap lotype add weakness seriousness this element [11]. particles communicated for intents purposes every nucleated cell particles principal explicit invulnerable actuated atoms related show, numerous investigations zeroed in space HLA Molecule [12] relationship propose job illness just have an expanded recurrence constructions; nonetheless, designs named [13]. Different illnesses that accounted for related the ordinary populace. They infection, Drowns disorder [14]. The greater part of the examination in the field of AA along these lines shows a solid case for the ramifications.

Etiopathogenesis

the diagnosis of Alopecia Areata has encountered extensive float for many years & various ways of thinking appointed shifted in the last part of the 1970s however resulting articles have shown no association [15]. A hereditary report Yanget al. tracked down of Alopecia Areata a polygenics added substance method of legacy [16]. It's been now broadly proposed that alopecia is an tissue immune system sickness with hereditary inclination and an ecological trigger [17]. A relationship among illustrated and announced patients with alopecia Areata are suffering. As of late, in the USA exhibited that a Non H-L-A atom includes the significant It very well may be a applicant quality and parts of an all inclusive HLa haplotypes this


can contribute to weakness & seriousness of its substance [18]. particles communicated for intents purposes every nucleated cell and platelets and particles has primary subclasses; they are found on explicit resistant cells, includes Beta cells, enacted T atoms related show, numerous investigations zeroed in on this space of the HLA particle [19]. relationship with propose job sickness.

- **Clinical features**

Hair falls in patches typically available too characterized patch of balding on the head yet any hair beard can included. Regularly, the area of patch is smooth and of typical skin tone with no optional change are like scaling and changes. Infrequently, it very well may be erythematous . Trademark ‘exclamatory imprint inside tightening, near extending. determination for the most part clinical. Dermoscopy is valuable in Doubtful cases. The scalp is the most widely recognize eyebrow hair like facial hair, hand hair, and might be influenced just as the whole body The ophiasis design alludes to a serious type of AA stretching out back transient edges. The influenced skin seems ordinary with no horribly apparent epidermal modifications, for example, anomalies [23]. structures ‘interjection discovered, smaller nearer might inside the spaces [24]. regularly at first need color bringing about blonde or white hair [25]. found part Little are commonplace, seldom different likewise hypothesized as an indication of intense contribution[26]

Types of alopecia Areata

Alopecia Areata



Differential Diagnosis-

In spite of the fact that alopecia is a variety of Not fearing Alopecia it is once a while mistaken for various assortments of scarring alopecia also. This is

additionally in light of the fact that numerous The initial step, accordingly is to recognize or decay. irritation is habitually, yet, Aggravation might be available. Eventually, histologic affirmation strategy affirm measure with fall of hair. A couple of elements 1 centrifugalcicatricial Tractional alopecia. principle analysis othervarieties of Cicatricial alopecia is portrayed by sketchy balding holes. Stopping can happen dependent basic Cause. continuous going bald with designed appropriation. look like exhaust. movement is might utilized ladies set up, taking after. Footing copies. Auxiliary timeworn as opposed to soft Innate three-sided intently Emulates AA. It isn't inborn as the name recommends, Appear ordinarily following 2 years old, infrequently expected recognize.

Histopathology

discoveries fluctuate length infection it's good four biopsies subcutaneous weight gain. example ought to prepared segment. On the off chance that solitary a solitary example is arranged, even areas will give a superior portrayal of the history . An evenly separated scalp biopsy is useful in affirming the analysis of AA yet in addition gives data about conceivable regrowth.[28] However detailed upward areas are sufficient to determine the diagnosis.[29] spot propelling boundary going bald. assists with review various evaluate thickness, follicle width, and to survey the extent of hair follicles in different tally short of what ordinarily demonstrates odds of .[30] The histopathologic highlights rely upon phase scene don't fluctuate with the [31]. intense are encircled ('bee hive') diminished expanded.

- **Management**

The executives of sufferers of Alopecia is a difficult undertaking various danger factor has involved in its No authoritative fix has been set up, and treatment has zeroed in chiefly on containing sickness movement. Effective and steroids have been the backbone of treatment, and have been utilized as first line specialists for the administration of the equivalent. It has been bridled of its overall calming impacts for AA For surrounded AA including under half of the primary convergence managed utilizing a measure needle in different infusions roughly 1 cm separated [35]. Beginning consequences of diagnosis regularly found. Extra medicines rehashed each 4 a month and a half.

Conclusion

AA is the basic type of going bald influencing the personal satisfaction of numerous patients. Hereditary helplessness, components, & auto- immunity fundamental etiological variables. examines had distinguished qualities making ready comprehension of There is lack of controlled investigations with respect to successful medicines backbone. Different medicines and . More up to date treatments are engaged at T-cell system and NK-cell actuating ligands. cyclosporine. With every diagnosis, results and cosmetically satisfactory improvements should be thought of. Backing components as neighborhood support gatherings ought to be shaped to give guiding to the influenced patients and mollify their mental comorbidities.

- **Reference**

1. AU Rashidi, T., Mahd, A.A., 2008. SO Treatment of persistent Alopecia areata with sulfasalazine. *Int. J. Dermatol.* 47 (8), 850.
2. Ay Se, Kavak, Can, Baykal, Guzin, Ozarmagan, et al, 2000. HLA in Alopecia areata. *Int. J. Dermatol.* 39, 598.
3. Baker, G.H.B., 1987. Psychological factors and immunity. *J. PsychoSom. Res.* 31, 1–10 [Links].
4. Barahmani, N., de Andrade, M., Slusser, J.P., et al, 2006. Major
5. Histocompatibility complex class I chain-related gene a polymorp and extended haplotypes are associated with familial Alopecia areata. *J. Invest. Dermatol.* 126, 74–78.
6. Brenner, R., 1979. Coincidences of alopecia areata, vitiligo, onychodystrophy, localized scleroderma and lichen planus. *Dermatologica* 159, 356–358.
7. Buhl, A.E., 1991. Minoxidil's action in hair follicles. *J. Invest.Dermatol.* 96, 73–74, 73S–74S.
8. Burton, J.L., Shuster, S., 1975. Large doses of glucocorticoid in the treatment of alopecia areata. *Acta*

Derm. Venereol. 55 493–496.

9. Camacho, F., 1997. Alopecia areata. Clinical characteristics and dermatopathology. In: Trichology: Diseases of the Pilosebaceous Follicle. Aula Medical Group S. A, Madrid, pp. 440–471.
10. Colon, E.A., Popkin, M.K., Callies, A.L., Dessert, N.J., Hordinsky, M.K., 1991. Lifetime prevalence of psychiatric disorders in patients With alopecia areata. Compr. Psychiatry 32, 245–251.
11. Dickerman, R.D., Jaikumar, S., 2001. The hiccup reflex arc and Persistent hiccups with high dose anabolic steroids: is the brainstem the steroid – responsive locus? Clin. Neuropharmacol. 24, 62–64.
12. Duncan, F.J., Silva, K.A., Johnson, C.J., King, B.L., Szatkiewicz, J.P., Kamdar, S.P., 2013. Endogenous retinoids in the pathogenesis of Alopecia areata. J. Invest. Dermatol. 133 (2), 33343. <http://dx.doi.org/10.1038/jid.2012.344> (Epub 2012 Sep 27).
13. Ellis, C.N., Brown, M.F., Voorhees, J.J., et al., 2002 Apr. Sulfasalazine for alopecia areata. J. Am. Acad. Dermatol. 46 (4), 541–544.
14. Fiedler, V.C., Wendrow, A., Szpunar, G.J., Metzler,

- C., DeVillez,R.L., 1990. Treatment resistant alopecia areata. Response to Combination therapy with minoxidil plus anthralin. *Arch. DermaTol.* 126 (6), 756–759.
15. Finner, Andreas.M., 2011. Alopecia areata: clinical presentation, diagnosis, and unusual cases. *Dermatol. Ther.* 24, 348–354.
 16. Fransway, A.F., Muller, S.A., 1988. 3 Percent topical minoxidil Compared with placebo for the treatment of chronic severe alopecia Areata. *Cutis* 41, 431–435.
 17. Freyschmidt-Paul, P., Happle, R., Hoffman, R., 2004. Alopecia areata in animal models–new insights into pathogenesis and treatment of a T cell-mediated autoimmune disorder]. *J. Dtsch. Dermatol. Ges.* 2 (4), 260–273.
 18. Friedli, A., Labarthe, M.P., Engelhardt, E., et al, 1998. Pulse Methylprednisolone therapy for severe alopecia areata: an open Prospective study of 45 patients. *J. Am. Acad. Dermatol.* 39, 597–602.
 19. Galbraith, G.M.P., Thiers, B.H., Fundenberg, H.H., 1984. An open Label trial of immunomodulation therapy with Inosiplex (Isoprinosine) in patients with alopecia totalis and cell mediated immunodeficiency. *J. Am. Acad. Dermatol.* 11, 224–230.

20. Garcia-Hernandez, M.J., 2000. CFM. Atypical clinical forms of Alopecia areata. In: Camacho Francisco, M.R., Price Vera, H.(Eds.), Hair and its Disorders: Biology, Pathology, and Manage-Ment. Martin Dunitz, London, pp. 228–231.
21. Gilhar, A., Kalish, R., 2006. Alopecia areata: a tissue-specific autoimmune disease of the hair follicle. *Autoimmun. Rev.* 5, 64–69.
22. Gupta, A.K., Ellis, C.N., Nickoloff, B.J., et al, 1990. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. *Arch.dermatol.* 126, 339–350.
23. Happle, R., Echternacht, K., 1977. Induction of hair growth in Alopecia areata with DNCB. *Lancet* 2, 1002–1003.
24. Hordinsky, M., Ericson, M., 2004. Autoimmunity: alopecia areata. *J.Invest. Dermatol. Symp. Proc.* 9, 73–78.
25. Hordinsky, M., Lorimer, S., Worel, S., 1995a. Innervation and Vasculature of the normal human and of the Brussels, Belgium.
26. Hordinsky, M.K., Kennedy, W., Wendelschafer-Crabb,

- G., Lewis, S., 1995b. Structure and function of cutaneous nerves in alopecia Areata. *J. Invest. Dermatol.* 104 (Suppl.), 28–29, 28S–29S.
27. Igarashi, R., Moroashi, M., Takeuchi, S., 1981. Immunofluorescence Studies on complement components in the hair follicles of normal Scalp and of scalp affected by alopecia areata. *Acta Derm. Venereol.* 61, 131–135.
28. Jiang, H., Yamamoto, S., Kato, R., 1995. Induction of anagen in telogen mouse skin by topical application of FK506, a potent Immunosuppressant. *J. Invest. Dermatol.* 104, 523–525.
29. Lawrence, I.D., 1998. Tacrolimus (FK506): experience in dermatology. *dermatol. Ther.* 5, 74–84.
30. Bark-Lynn Lew, M.D., Min-Kyung Shin, M.D., Woo-Young Sim, 2009. Acute diffuse and total alopecia: a new subtype of alopecia Areata with a favorable prognosis. *J. Am. Acad. Dermatol.* 60 (1), 85–93.
31. Madani, S., Shapiro, J., 2000. Alopecia areata update. *J. Am. Acad. Dermatol.* 42, 549–566.
32. Maria, Hordinsky, Marna, Ericson, 2004. Autoimmunity: Alopecia Areata. *J. Invest. Dermatol. Symp. Proc.* 9, 73–78.

33. McDonagh, A.J., Tazi-Ahnini, R., 2002. Epidemiology and genetics of Alopecia areata. *Clin. Exp. Dermatol.* 27, 405–409.
34. McMichael, A.J., 1997. The genetic epidemiology of autoimmune pathogenesis alopecia areata. *J. Eur. Acad. Dermatol. Venereol.* 9, 36–43.
35. Mohamed, Z., Bhouri, A., Jallouli, A., et al, 2005. Alopecia areata treatment with a phototoxic dose of UVA and topical 8-Methoxypsoralen. *J. Eur. Acad. Dermatol. Venereol.* 19, 552–555.
36. Odom, Richard B., Davidsohn, Israel, James, William D., Henry, John Bernard, Berger, Timothy G., 2006. Clinical diagnosis by laboratory methods. In: Elston, Dirk M. (Ed.), *Andrews' Diseases of the Skin: Clinical Dermatology*. Saunders Elsevier.
37. Olsen, E.A., 2003. Hair, in *Fitzpatrick's dermatology in general medicine*. In: Freedberg, I.M. (Ed.). McGraw-Hill, New York, pp.641–643.
38. Olsen, E.A., Hordinsky, M.K., Price, V.H., Roberts, J.L., Shapiro, J., Canfield, D., et al, 2004. National alopecia areata foundation. Alopecia areata investigational assessment guidelines. Part II. National Alopecia Areata

Foundation. *J. Am. Acad. Dermatol.* 51,440–447.

39. Pascher, F., Kurtin, S., Andrade, R., 1970. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and ensuing localized acneiform response. *Dermatologica* 141, 193–202.
40. Pasricha, J.S., Kumrah, L., 1996. Alopecia totalis treated with oral mini-pulse (OMP) therapy with betamethasone. *Indian J. Dermatol. Venereol. Leprol.* 62, 106–109.
41. Paus, R., 1996. Control of the hair cycle and hair diseases as cycling disorders. *Curr. Opin. Dermatol.* 3, 248–258.
42. Paus, R., Heinzelmann, T., Schultz, K.D., Furkert, J., Fechner, K., Czarnetzki, B.M., 1994. Hair growth induction by substance P. *Lab. Invest.* 71, 134–140.
43. Price, V.H., 1987. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. *J. Am. Acad. Dermatol.* 16, 730–736.
44. Price, V.H., Gummer, C.L., 1989. Loose anagen syndrome. *J. Am. Acad. Dermatol.* 20, 249–256.

45. Rangunatha, S., Inamadar, A.C., Palit, A., Sampagavi, V.V., Deshmukh, N.S., 2008. Diffuse nonscarring alopecia of scalp: an indicator of Early infantile scurvy? *Pediatr. Dermatol.* 25 (6), 644–646
46. Raud, J., Lundeberg, T., Brodda-Jansen, G., Theodorsson, E., Hedqvist, P., 1991. Potent anti-inflammatory action of calcitonin gene Related peptide. *Biochem. Biophys. Res. Commun.* 180, 1429–1435.
47. Rosenberg, E.W., Drake, L., 1976. Discussion of Dunaway DA. Alopecia areata. *Arch. Dermatol.* 112, 256
48. Ross, E.K., Shapiro, J., 2005. Management of hair loss. *Dermatol. Clin.* 23, 227–243.
49. Ruiz-Doblado, S., Carrizosa, A., Garcia-Hernandez, M.J., 2003. Alopecia areata: psychiatric comorbidity and adjustment to illness. *Int. J. Dermatol.* 42, 434–437.
50. Safavi, K.H., Muller, S.A., Suman, V.J., et al, 1995. Incidence of Alopecia areata in Olmsted County, Minnesota, 1975 through 1989. *Mayo Clin. Proc.* 70, 628–633.
51. Sharma, P.K., Jain, R.K., Sharma, A.K., 1990. PUVASOL therapy in Alopecia areata. *Indian J. Dermatol. Venereol. Leprol.* 56, 301–303.

52. Sharma, V.K., Dawn, G., Kumar, B., 1996. Profile of alopecia areata In Northern India. *Int. J. Dermatol.* 35 (1), 22–27.
53. Shimmer, B.P., Parker, K.L., 2001. *Goodman's and Gillman's: the Pharmacological Basis of Therapeutics*. McGraw-Hill, New York (pp. 1661–1663).
54. Strober, B., Siu, K., Alexis, A., et al, 2005. Etanercept does not Effectively treat moderate to severe alopecia areata: an open-label Study. *J. Am. Acad. Dermatol.* 52, 1082–1084.
55. Tan, E., Tay, Y.-K., Goh, Ch.-L., et al, 2002. The pattern of Alopecia areata in Singapore – a study of 219 Asians. *Int. J. Dermatol.* 41, 748–753.
56. Tan, E., Tay, Y.K., Giam, Y.Ch., 2002. A clinical study of childhood Alopecia areata in Singapore. *Pediatr. Dermatol.* 19, 298–301.
57. Taylor, M., Ashcroft, A.T., Messenger, A.G., 1993. Cyclosporin A Prolongs human hair growth in vitro. *J. Invest. Dermatol.* 100,237–239.

58. Thappa, D.M., Vijayikumar, M., 2001. Alopecia areata. *Indian J.Dermatol. Venereol. Leprol.* 67, 188, 188–188.

59. Tosti, A., La Placa, M., Placucci, F., et al, 1996. No correlation Between CMV and alopecia areata. *J. Invest. Dermatol.* 107, 443.

60. Tosti, A., Piraccini, B.M., Pazzaglia, M., et al, 2003. Clobetasol Propionate 0.05% under occlusion in the treatment of alopecia Totalis/universalis. *J. Am. Acad. Dermatol.* 49, 96–98.

61. Trueb, R.M., 2010. Systematic approach to hair loss in women. *Indian Clin. Updat.-Dermatol.* 2 (4), 284–297.

62. Van der Steen, P., Boezeman, J., Duller, P., Happle, R., 1992. Can Alopecia areata be triggered by emotional extensive hair loss. *Acta Dermato.Venereol. (Stockh)* 72, 279–280.

63. Wasserman, D., Guzman-Sanchez, D.A., Scott, K., Mc Michael, A., 2007. Alopecia areata. *Int. J. Dermatol.* 46, 121–131. Whiting, D.A., 2003. Histopathologic features of alopecia areata: a New look. *Arch. Dermatol.* 139 (12), 1555–1559.

64. Whiting, D.A., 2003. Histopathologic features of alopecia areata: a New look. *Arch. Dermatol.* 139 (12), 1555–1559. Whitmont, K., Cooper, A., 2003. PUVA treatment of alopecia areata Totalis and universalis: a retrospective study. *Australas J. Dermatol.* 44, 106–109.

65. Yang, S., Yang, J., Liu, J.B., et al, 2004. The genetic epidemiology of Alopecia areata in China. *Br. J. Dermatol.* 151, 16–23.

66. Yamamoto, S., Jiang, H., Kato, R., 1994. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive Agent. *J. Invest. Dermatol.* 102, 160–164.

